Recent Updates
Recently added Catalysts

Trandolapril

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jul 19, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment104
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01164787Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting ConditionsPHASE1 COMPLETED 52Mar 1, 2006May 1, 2006Jul 19, 20101 India
NCT01164800Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed ConditionsPHASE1 COMPLETED 52Mar 1, 2006May 1, 2006Jul 19, 20101 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence is based on Cmax and AUC parameters.
3 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TrandolaprilEXPERIMENTALTrandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
Mavik®ACTIVE_COMPARATORMavik® 4 mg Tablets of Abbott Laboratories, USA.
Interventions
NameTypeDescription
TrandolaprilDRUGTrandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
MavikDRUGMavik® 4 mg Tablets of Abbott Laboratories, USA.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy human subjects within the age range of 18 to 45 years * Non-smokers since at least six months * Willingness to provide written informed consent to participate in the study * Body-mass index of ≥ 18.5 kg/m2 and ≤24.9 kg/m2, with body weight not less than 50 kg * Absence...

Countries:India
Unlock Eligibility Criteria